Pregnancies in women with cardiomyopathy had no maternal deaths in a UK study

Cardiomyopathy — disease of the heart muscle itself — is one of the conditions that makes pregnancy counselling hard. The heart's workload rises substantially through gestation and peaks around delivery, and for a woman whose heart muscle is already weakened or thickened, clinicians have long worried that pregnancy could tip her into heart failure or a dangerous rhythm. European guidance treats several of these conditions as high-risk and, in the most severe cases, as a reason to advise against pregnancy altogether [s2].

A prospective cohort study published in BJOG on 9 October puts recent national numbers to that worry [s1].

What was done

Researchers used the UK Obstetric Surveillance System, a network through which clinicians across the country report rare pregnancy conditions. Cases were women with a pre-pregnancy diagnosis of cardiomyopathy — dilated, hypertrophic, arrhythmogenic right ventricular, or previous peripartum cardiomyopathy. Details were notified monthly from 1 June 2021 until 31 May 2024 [s1].

This is an observational design, not a trial. It describes what happened to women who became pregnant with these diagnoses in the UK over three years; it cannot say what would have happened had they not been managed the way they were. Its value is as a picture of real outcomes under contemporary care.

Who was included

The study identified 210 pregnancies in 209 women [s1]. The largest group had dilated cardiomyopathy — 103 of 209 (49.3%). Hypertrophic cardiomyopathy accounted for 40 of 209 (19.1%), previous peripartum cardiomyopathy for 24 of 209 (11.5%), and arrhythmogenic right ventricular cardiomyopathy for 11 of 209 (5.3%). A further 31 of 209 (14.8%) had cardiomyopathies classed as "other" [s1].

That distribution matters for reading the results. Dilated and peripartum cardiomyopathy, which together make up most of the cohort, are the forms most associated with pumping failure, so the group is not weighted toward the mildest disease.

What happened

The headline result is an absence: there were no maternal deaths [s1].

Cardiac complications did occur but were uncommon. Ten percent of women had a documented episode of heart failure during pregnancy, and 8% a documented arrhythmia [s1]. The authors describe the overall rate of maternal cardiac complications as small [s1].

Deliveries were, for the most part, close to term. Among 206 singleton pregnancies, the median gestation at delivery was 38.1 weeks [s1]. Newborns were more likely than the general population to need specialist care: of the babies for whom data were recorded, 36 of 180 (20%) were admitted to a neonatal unit [s1].

The authors' conclusion is measured. Pregnancies in women with cardiomyopathy managed in the UK typically have successful outcomes, consistent with previously published data, and the rate of maternal cardiac complications was small [s1].

How to read it

Three cautions keep this from being a blanket reassurance.

First, this is a selected population. These are women who became pregnant and were reported to a surveillance system — many with cardiomyopathy may have been advised against pregnancy, or have chosen not to proceed, and they are not in the denominator. The guideline framework explicitly counsels against pregnancy in the highest-risk presentations [s2]. A cohort of those who went ahead, under specialist obstetric and cardiology care, cannot tell you the risk for someone whose disease is more severe or whose care is less coordinated.

Second, the absolute numbers are small. With 210 pregnancies, zero maternal deaths is genuinely reassuring but comes with wide statistical uncertainty; it does not establish that the death rate is zero, only that deaths were rare in this series.

Third, "documented" heart failure and arrhythmia depend on what was recorded and reported through a surveillance network, which can undercount events that were managed quietly or missed.

Why it matters

For a woman with cardiomyopathy weighing pregnancy, the practical question is not whether risk exists but how large it is under good care. This study's contribution is a recent, national, prospective answer for the UK: among women who proceeded and were managed within the system, most pregnancies ended well, serious cardiac events were the minority, and no mother in the series died [s1]. That sits alongside, rather than replaces, the guideline-based individual risk assessment that separates the women for whom pregnancy is reasonable from those for whom it is not [s2].

This article is informational and does not constitute medical advice.